Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

5.610 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,751
Open 5.610
Bid (Size) 5.610 (1)
Ask (Size) 5.640 (1)
Prev. Close 5.610
Today's Range 5.610 - 5.610
52wk Range 5.600 - 11.69
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner. 
Via The Motley Fool
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The biotech has bounced back some in the past year. 
Via The Motley Fool

Performance

YTD
-43.79%
-43.79%
1 Month
-27.33%
-27.33%
3 Month
-33.29%
-33.29%
6 Month
-15.00%
-15.00%
1 Year
-30.40%
-30.40%

More News

Read More
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Via The Motley Fool
The Latest Analyst Ratings For Editas Medicine
Via Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
Via Investor's Business Daily
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 2/28
Via Investor Brand Network
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Earnings Outlook For Editas Medicine
Via Benzinga
The Latest Analyst Ratings for Editas Medicine
Via Benzinga
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
2 Under-the-Radar Stocks With Incredible Upside Potential
Via The Motley Fool
Could Editas Medicine Become the Next CRISPR Therapeutics?
Via The Motley Fool
7 Mighty Healthcare Stocks Changing the Game of Medicine
Via InvestorPlace
Down 88%, Could Editas Medicine Be a Good Investment Now?
Via The Motley Fool
3 Stocks to Buy in the Booming Field of Gene Editing
Via InvestorPlace
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Via The Motley Fool
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
2 gene-editing stocks reshaping hereditary disease treatments
Via MarketBeat
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
Via The Motley Fool
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.